News & Views | Published:


First point-of-care PSA test for prostate cancer detection

The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    U.S. Food and Drug Administration. Recently-approved devices: Sangia Total PSA Test - P170037. FDA (updated 31 Jan 2019).

  2. 2.

    U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED). FDA (2019).

  3. 3.

    OPKO Diagnostics. Instructions for use. FDA (2019).

  4. 4.

    Loeb, S. et al. How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J. Urol. 196, 721–726 (2016).

  5. 5.

    Centers for Medicare & Medicaid Services. Clinical laboratory improvement amendments (CLIA). CMS (updated 24 Feb 2019).

  6. 6.

    Centers for Medicare & Medicaid Services. How to obtain a CLIA certificate of waiver. CMS (2006).

Download references

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Michael A. Gorin.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: A microfluidic-based immunoassay employing Sangia technology.